(BFA) BASF Se
Summary
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |
|---|---|---|
|
|
||
| 28-10-11 | RNS |
|
|
RNS Number : 0628R Oao Gazprom 28 October 2011 Gazprom and Wintershall agree on framework for asset swap
Today (October 28, 2011) a framework agreement which sets out the terms for the planned asset swap to further expand the successful cooperation has been signed in Ludwigshafen by Alexey Miller, Chairman of the Management Committee of OAO Gazprom, and Dr. Kurt Bock, Chairman of the Board of Executive Directors of BASF SE. According to the agreement, two further blocks of the Achimov formation of the Urengoy field in western Siberia will be developed by the two companies. Wintershall, a wholly owned subsidiary of BASF SE, will initially hold a working interest of 25 percent plus one share in the development of two blocks. Wintershall retains the option of increasing this shareholding to 50 percent. The framework agreement stipulates that Gazprom will receive interests of equal value in selected exploration and production projects by Wintershall in the North Sea (Netherlands, UK). Gazprom will ultimately receive half of Wintershall's shares in these concessions.
"The constructive partnership between Gazprom and BASF/Wintershall enables us to tackle technically complex and ambitious projects. Together with Wintershall, we want to expand gas production from the Achimov layers of the Urengoy deposit and cooperate in E&P projects in the southern North Sea, where Wintershall has been operating successfully for decades, for our mutual benefit," said Alexey Miller.
"The joint production between our oil and gas subsidiary Wintershall and Gazprom from the Achimov deposit is an impressive example of our long-standing success model: cooperation in the spirit of partnership and complementing each other's strengths along the entire value adding chain. Further expanding our shared production is an important step in our partnership with Gazprom, which stretches back over 20 years," said Dr. Kurt Bock.
This information is provided by RNS The company news service from the London Stock Exchange More |
||
| 02-07-10 | AFX UK Focus |
|
|
SAN FRANCISCO, July 2 (Reuters) - Two shallow-water rigs owned by Rowan Cos Inc will be departing the U.S. Gulf of Mexico later this year, and analysts said on Friday they expect them to end up in the Middle East.
(Reporting by Braden Reddall, editing by Gerald E. McCormick) Keywords: ROWAN/RIGS (braden.reddall@thomsonreuters.com; +1 415 677 2543; braden.reddall.reuters.com@reuters.net)
COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. More |
||
| 02-07-10 | AFX UK Focus |
|
|
LONDON, July 2 (Reuters) - Chemical industry leader BASF has mandated Credit Agricole CIB, BNP Paribas and ING to arrange a 3 billion euros ($3.67 billion) bridge loan related to its purchase of Cognis, a spokeswoman said on Friday.
(Reporting by David Cox & Zaida Espana, editing by Will Waterman) ($1=.8172 Euro) Keywords: BASF/COGNIS (zaida.espana@reuters.com; +44-20-7542-7996; Reuters Messaging zaida.espana@reuters.com@reuters.net)
COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. More |
||
| 25-06-10 | AFX UK Focus |
|
|
AMSTERDAM, June 25 (Reuters) - Solvay says:
((Amsterdam Newsroom; amsterdam.newsroom@reuters.com; +31 20 504 5000)) ( For more double click on )
COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. More |
||
| Result Pages: 1 | ||||
| Date/Time | Subject | Author | ||
|---|---|---|---|---|
| Mon 23:45 | ||||
|
|
||||
|
|
||||
| 30-01-12 | ||||
|
|
||||
|
|
||||
|
https://service.mail.com/dereferrer/?target=http%3A%2F%2Fclicks.moneymorning.com%2F%2Ft%2FAQ%2FAAko0A%2FAAk5Lw%2FAAW57w%2FAQ%2FA0aaKA%2FLJnC&lang=en
http://clicks.moneymorning.com//t/AQ/AAko0A/AAk5Lw/AAW57w/AQ/A0aaKA/LJnC |
||||
| 06-01-12 | ||||
|
|
||||
|
|
||||
| 05-01-12 | ||||
|
|
||||
|
|
||||
|
5 January 2012
("ValiRx" or the "Company") Acquisition of Finnish biomarkers business by ValiFinn together with associated patents and Intellectual Property ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that ValiFinn Oy, its wholly owned subsidiary, has acquired from Pharmatest Services Oy ("Pharmatest") of Oulu, Finland, its biomarkers business unit together with 5 families of patents and patent applications and related intellectual property ("IP"). The consideration is a payment of EUR75,000 and the allotment of 15,000,000 shares in ValiRx Plc, credited as fully paid. There is also an obligation to pay a royalty to Pharmatest from future revenues relating to the IP and for the life of the patents. The biomarkers business unit comes with a revenue stream, which is derived from the provision of contract research services to pharmaceutical companies who are utilising its library of biomarkers and it will form a new division at ValiFinn. Strategically, the acquisition will enhance the Group's R&D capability, as the specialist biomarker expertise within the unit is leveraged to advance in-house the development of companion biomarker diagnostics to complement ValiRx's therapeutics, its existing intellectual property and companion diagnostic activities. Epigenomics is a rapidly advancing field and pairing a prognostic and/or predictive biomarker diagnostic with a targeted drug is emerging as a key part of personalised medicine, particularly in cancer patients. The Directors of ValiRx believe therefore that the IP acquired can add considerable value to the Group and they look forward to the biomarker unit's involvement in ValiRx's forthcoming clinical trials, and to benefiting from the favourable environment for regulated medical and clinical studies in the Nordic region. As reported on 18 August 2011, ValiFinn will be conducting in Finland the management of certain aspects of ValiRx's late preclinical work on its compound, VAL201, to develop a treatment for hormone induced refractory prostate cancer among other conditions. Issue of Equity In relation to the share based payment described above the Company has issued 15,000,000 new ordinary shares at a price of 0.52 pence per share. The new ordinary shares will rank pari passu with the existing ordinary shares. Application for the new ordinary shares has been made to the London Stock Exchange and trading in these shares is expected to occur on or around 10 January 2012. Following the issue of equity, the share capital of the company will comprise 1,059,562,609 ordinary shares of 0.1 pence each. Dr Satu Vainikka, CEO, commented: "I am delighted to welcome our new colleagues to the Group and am pleased to see ValiRx moving into the fast developing biomarkers' space. As is detailed below, biomarkers are crucial for detecting cancer at an early stage and they are also key in optimising therapeutic strategy and monitoring therapeutic success. It is a market that is rapidly growing in size with the potential benefit for patients being significant, in addition to potential cost savings derived from across the pharmaceutical industry. I look forward to our late pre-clinical work progressing to the stage whereby value in both this newly acquired IP and the VAL201 compound is further crystalised". http://bit.ly/xidZ9J ValiRx inks biomarker deal 7:38 am by Ian Lyall Biomarkers are crucial for detecting cancer at an early stage. ValiRx (LON:VAL) said this morning it is acquiring the biomarkers arm of Finnish firm Pharmatest in a deal that values the business at £137,000. The AIM-listed drug developer is paying around £62,000 in cash (75,000) and will issue Pharmatest with 15 million shares worth just over £75,000 at todays prices. Pharmatest may also be entitled to royalty payments. Strategically, the acquisition will enhance t |
||||
|
|
||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Markets: FTSE 100 in the black as Bank announces more QEEditor's Pick:
View from the top: Tangiers Petroleum interviewEditor's Pick:
Greece strikes bail-out agreementEditor's Pick:
Bank announces £50bn quantitative easing packageEditor's Pick:
Mixed outlook for trio of mining giantsEditor's Pick:
Barryroe update boosts Providence and LansdowneEditor's Pick:
Vodafone reveals weaker-than-expected performanceEditor's Pick:
Nighthawk announces new Jolly Ranch investmentEditor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
George Godber’s AIM stock picks

